Assessing the applicability of trial evidence to a target sample in the presence of heterogeneity of treatment effect

Abstract

Purpose To propose methods for the quantitative assessment of the applicability of evidence from a trial to a target sample using individual data. Methods Demonstration was with a trial of drug therapy to prevent mortality and an accompanying registry of people with heart failure. Principal components analysis with biplots did not identify measurement discrepancies. Multiple imputation with chained equations addressed missing predictor values. A proportional hazards model with interaction term, including graphical interpretation and a multivariate interaction test, identified heterogeneity of treatment effect. An interval of homogeneity of treatment effect was the interval of the baseline risk of outcome in which no two treatment effects were statistically significantly different. Absolute risk reduction for individuals was estimated for both benefit and harm outcomes and presented in a bivariate treatment effects scatterplot. Results Overall, the trial evidence applied to most of the registry according to overlapping distributions of estimated benefit and harm. However, 52% of trial and 33% of registry participants were estimated to have net benefit, and 14% of trial and 36% of registry participants were estimated to have strong net harmful treatment effect, that is, the individual estimate of harm was more than twice the estimate of benefit. Conclusions The proposed methods provide quantitative assessment of the applicability of trial evidence to a target sample. They combine the strengths of different study designs, namely, unbiased effects estimation from trials and representation in observational studies, while addressing the practical challenges of combining information, namely, measurement discrepancies and missing data.

Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to Benefit

“…We may make the assumption that the information obtained at the group level is applicable to all individuals in a trial, but even within the RCT there may be meaningful heterogeneity of treatment effect. [50–53] Thus, applying the results of a trial to an individual patient with multimorbidity could substantially over- or underestimate TTB for the individual.…”

Clinician's Checklist for Reading and Using an Article About Patient-Reported Outcomes

“…Results should be presented for important patient subgroups that might be expected to show heterogeneity of treatment effects. 20 Ideally, these subgroups should be identified a priori or results should be qualified as exploratory.…”

Perils and Potentials of Self-Selected Entry to Epidemiological Studies and Surveys

“…When informing policy, inference to identified reference populations is key, and both methods development and application to achieve this goal burgeon (Frangakis, ; Greenhouse et al ., ; Pressler and Kaizar, ; Schumacher et al ., ; Stevens et al ., ; Stuart et al ., ; Stuart, ; Turner et al ., ; Weiss et al ., ). Stuart et al .…”